MYC and Familial prostate cancer: The treatment of C4-2 prostate cancer cells (more invasive derivative of LNCaP cells and with comparatively lower expression of PrKD1) with MYC inhibitor increased the transcriptional expression of PrKD1 confirming the negative regulatory role of MYC on PrKD1 expression (Figure 3D).